Quince Therapeutics
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD415—622m (Dealroom.co estimates May 2018.)
Share price
$0.76 CRTX
South San Francisco California (HQ)
Authorizing premium user...